Metabolomic Technologies develops patented, metabolomic-based, diagnostic tests to detect adenomatous polyps and colorectal cancer (CRC). Its product, PolypDx, is a urine-based test with high sensitivity for detecting adenomatous polyps, the precursor to colorectal cancer. It aims to provide doctors with a tool for early screening and detection.